companydata.dkcompanydata.dk

NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2016

CVR: 24257924

Source: annual report 2016, Danish Business Authority

01/01/2016 – 31/12/2016

NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2016. In 2016, the company reported a net result of DKK 1,694,000 compared with DKK 1,879,000 the year before. Equity in the 2016 report amounted to DKK 16,116,000. The solvency ratio was 99.9%.

Profit/Loss
DKK 1,694,000
Equity
DKK 16,116,000
Total Assets
DKK 16,138,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2016--1.7M16.1M-
2015--1.9M14.4M-
2014--3.2M12.5M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like NOVO NORDISK PHARMACEUTICALS A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2016

NOVO NORDISK PHARMACEUTICALS A/S: The 2015 annual report is outMay 10, 2016

NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2015. The net result was DKK 1,879,000.

About NOVO NORDISK PHARMACEUTICALS A/S

NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.

Source: annual report 2025, Danish Business Authority